Loading Events

« All Events

  • This event has passed.


November 14, 2016 @ 7:30 am - 11:00 am

$40 – $55


NOVEMBER 14, 2016, 7:30AM TO 10:00AM


FOLEY HOAG LLP, Seaport West, 155 Seaport Boulevard, Boston
For Driving and Parking Information, Click Here.

Program Description:

Getting an idea to the point where it can attract investors is one of the hardest things an entrepreneur can do. No matter how sound an idea is, or how slick a presentation might be, there is no substitute for experience. Join us for a panel discussion of trends and issues to consider in seeking funding and life science investing.

  • What are the opportunities and challenges?
  • How do you analyze and present your technology, team, and requirements?
  • What are the different stages of the business and how might team requirements change?
  • What investment vehicles should be considered depending on the business stage?
  • What elements drive enterprise value and ability to attract capital at different stages?
  • Should you accept Reverse Vesting of Founder Equity / Founder Vesting?
  • Is it unhealthy to raise too much or too little money?
  • What are the strategies and opportunities for finding sources of capital?
  • Is there a “Valley of Death”?
  • Why should the entrepreneur seek to find the “right fit” and not just any investor?

Come join this timely, lively, blue ribbon panel of experts. Ask them questions and contribute your insights during the audience interactive segment.

Keynote Speaker:

David F. Hendren, Managing Director, New Technology Ventures

David has extensive experience in funding and building successful ventures from incubation to exit, with particular expertise in healthcare, life science, technology, and healthcare service areas. His 25+ year career has afforded broad perspective from virtually all sides of the table with roles including VC, entrepreneur, CEO, leader, and advisor.


Hemmie Chang, Partner, Chair, Licensing & Strategic Alliances Practice, Foley Hoag, LLP


Paul J. Mraz, Managing Partner, OnPoint Advisors, LLC
James E. Muller, M.D., Cardiologist at CIMIT and affiliated with Harvard Medical School, MGH and MIT
Patrick O’Donnell, CEO, ProteoThera, Inc.

Who Should Attend:

CEOs, CTOs, CFOs, clinicians, technologists, investors, and business experts seeking a better understanding of seeking capital, or looking to improve performance on their next round.

What to expect:

Overview of funding sources, investment instruments and term sheets, financial modeling, elements of good investor presentations, Intellectual Property requirements, and managing to an exit.


Hemmie Chang, Partner, Chair, Licensing & Strategic Alliances Practice, Foley Hoag, LLP

As Chair of Foley Hoag’s Licensing & Strategic Alliances Practice Group, partner Hemmie Chang regularly handles high profile intellectual property matters. Clients routinely benefit from Hemmie’s strategic business perspective and legal acumen from her two-plus decades of experience within the life sciences, energy and cleantech and technology sectors. She advises both established and emerging companies on a wide variety of licensing matters, from development to marketing deals – all of which involve a broad range of intellectual property assets, from brand names to copyright, patents to trade secrets. Hemmie is also very active within the firm’s Business Department and Life Science and Technology practice groups.

Hemmie is often sought out for comment as an expert on licensing and strategic alliance topics. She was invited to write “Partnering Prenuptials: Translating Priorities into Deal Terms” for The Burrill Report (June 2013), and has been quoted in the World Intellectual Property Review and The Pink Sheet, “In 2012, Buyer’s Market Made Alliances Rarer,” January 7, 2013.

David F. Hendren, Managing Director, New Technology Ventures

David Hendren has extensive experience in funding and building successful ventures from incubation to exit, with particular expertise in healthcare, life science, technology, and healthcare service areas. His 25+ year career has afforded broad perspective from virtually all sides of the table with roles including VC, entrepreneur, CEO, leader, and advisor, as well as sophisticated knowledge of strategy, commercializing novel technologies, driving adoption of new technologies and business models in healthcare, and starting-up, financing, scaling, and operating new, emerging, and growth-stage enterprises. His experience includes medical devices, diagnostics, drugs, healthcare IT, life science tools, e-health, technology enabled services, and structures and programs for all phases of healthcare delivery and payment, management services, and infrastructure support involving virtually all parties and points on the continuum of care. Having architected, launched, managed, and worked with ACOs, integrated networks, and other innovative models, David has a particularly sophisticated understanding of trends and drivers that will define all aspects of healthcare, healthcare technology, and the business of healthcare going forward, as data-driven quality and value-based models have emerged and evolved, and other drivers including changing demographics, economic pressure, political imperatives, and changing consumer behavior have influenced markets.

David received his JD from Northwestern University and his AB from Dartmouth College. He has written, spoken, and taught on topics including venture finance, entrepreneurship, and management, and has served as Entrepreneur in Residence at Babson College, a leading graduate and undergraduate program for entrepreneurship.

Paul J. Mraz, Managing Partner, OnPoint Advisors, LLC

Paul Mraz has been active in the medical device and life sciences industry for 25+ years, in companies large and small, mostly as an entrepreneur – both venture backed and privately funded) – with roles in executive management (14 years as CEO), corporate strategy, product development and marketing, sales management and business development – all on a global basis.

In 2013, Mr. Mraz founded and is the managing partner of OnPoint Advisors, LLC, a business strategy and leadership consulting firm providing tailored “CEO-in-Residence” ℠ services and business development expertise to a wide variety of clients in the life sciences industry. Prior to OnPoint Advisors, Mr. Mraz served as president and CEO of Cerapedics, Inc., a venture-backed medical device and biologics company. Previously, Mr. Mraz served as chairman and CEO of Angstrom Medica (acquired by RTI Surgical); was a principal of Link Spine Group (acquired by Johnson & Johnson (DePuy Synthes) in June 2003); and, in his earlier experiences, was a key management team member of Figgie Medical Systems, Ortho Development Corporation (acquired by Japan MDM) and Marlow Surgical Technologies, Inc. (acquired by Cooper Surgical) as well as DePuy, Inc. (where he began his professional career in Warsaw, IN) and DePuy Spine (formerly AcroMed Corporation) – both acquired by Johnson & Johnson in 1998.

Mr. Mraz served as a director of superDimension, Ltd. until its acquisition by Covidien in May 2012 and was also a board member of Spirus Medical, Inc. (acquired by Olympus in July 2011). For 6 years, Mr. Mraz served as an operating partner for Point Judith Capital (Boston, MA), a venture capital firm focused on early stage investing in the internet and mobile technology, healthcare technology and clean technology industries.

Mr. Mraz received a bachelor of science degree in mechanical engineering from Lafayette College (Easton, PA) and a master of science degree in mechanical engineering and biomechanics from Case Western Reserve University (Cleveland, OH). He holds nine US patents for various medical devices and technologies.

James E. Muller, M.D. is a cardiologist at CIMIT which is affiliated with Harvard Medical School, MGH and MIT.

Dr. Muller has conducted many studies of the triggering of onset of cardiovascular disease, which led to formulation of the concept of the vulnerable coronary plaque. In 1998 he founded Infraredx, Inc, a company which developed a near-IR and IVUS catheter to identify the plaques which cause heart attacks. The company was acquired by Nipro, Inc. in 2015, and the pivotal clinical trials will be completed in 2017 and 2018. He has extensive experience in fund-raising from multiple sources.

Dr. Muller is also a co-founder of International Physicians for Prevention of Nuclear War, which was awarded the 1985 Nobel Peace Prize.

Patrick O’Donnell, CEO and Co-Founder, ProteoThera, Inc.

For the past 24 years, Patrick O’Donnell has established a successful track record in the medical device, biologics, and biomaterials industries with technologies in the orthopedic, spine, neurosurgery, sports medicine, interventional radiology, vascular and, metabolic disorders markets.

As a CEO of tissue regenerative and medical device companies, Mr. O’Donnell has raised over $85M in the past six years to fund and execute the product development and clinical programs towards regulatory milestones. Mr. O’Donnell currently serves as the Founder, Director, and Chief Executive Officer of ProteoThera, Inc., an early stage biotech company with matrix-binding protein fusion technology for local delivery of small molecules and proteins to address articular joint inflammatory diseases.

Prior to ProteoThera, Mr. O’Donnell held executive leadership roles at several organizations including; interim CEO to lead the turn-around initiative of EndoSphere, Inc.; the CEO of cartilage regeneration company’s Histogenics Corporation and Prochon BioTech; and the Director of Global Marketing at Confluent Surgical. Mr. O’Donnell began his career at J & J DePuy Spine where he worked for thirteen years in commercial positions of escalating responsibility.


November 14, 2016
7:30 am - 11:00 am
$40 – $55
Event Tags:
, , ,


FOLEY HOAG LLP, Seaport West,155 Seaport Boulevard
Boston,MAUnited States
+ Google Map

Leave a Reply

Your email address will not be published. Required fields are marked *

Follow us!

Send this to a friend